Sony Pictures, Apollo Global Reportedly In Talks to Jointly Bid for Paramount 
Samsung Targets Beijing’s EV Semiconductor Market at Auto China 2024 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Will global oil supply be at risk if Iran and Israel pull the Middle East into war? 
SPC Group’s Paris Baguette Inaugurates First Bakery Shop in the Philippines 
Coca-Cola Launches Global 'Recycle Me' Campaign to Champion Recycling 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Kawhi Leonard and New Balance Launch the Highly Anticipated KAWHI IV Sneaker 
Food prices will climb everywhere as temperatures rise due to climate change – new research 
Kia Unveils $15,000 EV2, Spearheading Affordable Electric Vehicle Drive 
Tesla Cybertruck Recall: NHTSA Flags 3,878 Units for Pedal Issue 
5 Reasons Businesses Can’t Afford Not to Get Fleet Maintenance Software 
Adidas Unveils Innovative Team Kits for Paris 2024 Olympics and Paralympics 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
